Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002319 · ClinicalTrials.gov registry record · Phase 3
A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma
A Phase 3 study, sponsored by Sequus Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00002319: Completed Phase 3 study, sponsored by Sequus Pharmaceuticals.
NCT00002319 is a Phase 3 study that has completed, run by Sequus Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002319, a Phase 3 study, has completed, sponsored by Sequus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
To evaluate the safety and effectiveness of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the long-term treatment of AIDS-related Kaposi's sarcoma (KS) in patients who previously had good responses to DOX-SL in controlled studies of limited duration, or those with KS who discontinued treatment with another Kaposi's sarcoma therapy because of inadequate efficacy or unacceptable toxicity. To provide a defined protocol for Kaposi's sarcoma patients for whom DOX-SL therapy is indicated.
Interventions
- DRUG Doxorubicin hydrochloride (liposomal)
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
What the finished NCT00002319 record still lists
NCT00002319 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Doxorubicin hydrochloride (liposomal) is the first listed.
NCT00002319 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002319 about?
NCT00002319 is a clinical study titled "A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma". To evaluate the safety and effectiveness of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the long-term treatment of AIDS-related Kaposi's sarcoma (KS) in patients who previously had good responses to DOX-SL in controlled studies of limited duration, or those with KS who discontinued treat...
What is the current status of trial NCT00002319?
This trial is currently completed. It is a Phase 3 study.
What interventions are being tested in trial NCT00002319?
The interventions under investigation include: Doxorubicin hydrochloride (liposomal) (DRUG).
Who is sponsoring clinical trial NCT00002319?
This trial is sponsored by Sequus Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.